Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer

BACKGROUND: The mortality rate of ovarian cancer (OC) ranks first among female genital tract malignant tumors, which seriously threatens women’s life and health. Because of its insidious onset and poor prognosis, it has become a thorny problem in the clinic, especially for patients with platinum-res...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yawen, Zhang, Xiaoyan, Li, Lian, Yang, Wen, Yan, Zhifeng, Gu, Chenglei, Zhang, Zhe, Zhou, Jiahuan, Liu, Lulu, Ye, Mingxia, Meng, Yuanguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480580/
https://www.ncbi.nlm.nih.gov/pubmed/36118677
http://dx.doi.org/10.2147/OTT.S375643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480580/
https://www.ncbi.nlm.nih.gov/pubmed/36118677
http://dx.doi.org/10.2147/OTT.S375643

Ejemplares similares